Movement disorders:SCA3的轴向和径向共济失调,如何随时间变化

2022-07-11 Freeman MedSci原创

SCA3患者的轴向和径向共济失调的时间动态差异如何

脊髓小脑共济失调3型(SCA3)是一种破坏性的神经退行性疾病,主要影响小脑和桥脑深部核团、基底神经节和脊髓。尽管发病率有很大的地域差异,但它被认为是全世界最常见的显性遗传性共济失调,估计占受影响家庭的20%-50%。 SCA3是由ATXN3基因中一个不稳定的多聚谷氨酰胺编码的CAG重复扩展引起的,它引发了一系列复杂的事件,最终导致广泛的神经元损失。

图1: 论文封面图

过去15年见证了该领域的重要发展,包括共济失调评估和评级量表(SARA)的构建和验证,临床前疾病阶段的定义,欧洲和美国研究联盟的建立,以及大规模纵向研究的实施。 然而,这些努力主要集中在总体共济失调严重程度的进展上,如SARA总分的年度变化,而没有具体评估单一SARA项目或将轴性与阑尾性项目分组的子分数的时间动态。

最近在弗里德里希共济失调(Friedreich Ataxia)中描述了轴性和径性体征的自然历史差异,在一项涉及SCA3患者的单中心研究中也注意到了这种差异。对项目得分的仔细调查不仅可以提供有关退行性小脑疾病临床演变的更详细的信息,而且还可能对SARA作为治疗试验中(主要)结果测量的应用产生重要影响。

藉此,荷兰拉德堡德大学的Roderick P.P.W.M. Maas等人, 结合使用来自SCA3突变携带者的大型国际队列的横断面和纵向数据,试图研究SARA及其各个项目的进展模式,并特别关注轴向与阑尾的分值。此外,还研究了人口统计学、临床和遗传因素是否与轴向和阑尾分值的进展率有不同程度的共线性,以及SARA项目得分的年度变化是否与SCA3的相应功能测量的变化相关。

这个研究涉及11个欧洲和2个美国的前瞻性多国队列研究中,对223名SCA3患者的SARA评分进行了纵向测定,并在1年后进行了随访评估。

他们发现:SARA得分从10分增加到20分主要是由轴向和语言项目驱动的,而阑尾项目的贡献明显较小。

追指(finger-chase)和鼻指(nose finger)测试的分数不仅在基线上显示出最低的变异性,而且在随访中也显示出最小的恶化。与全套SARA项目相比,省略这两项测试会使治疗试验的样本量要求降低。

图2:论文结果图

性别与SARA总分和阑尾分的变化有关,但与轴向分的变化无关,男性的进展明显更快。尽管个体间存在相当大的差异,但病程超过10年的受试者的SARA评分的平均年进展率比发病后10年内的受试者高约3倍。

该研究的重要意义在于:为SCA3患者的轴向和径向共济失调的时间动态差异提供了证据,这将有助于为临床试验的设计和新的(特定病因)结果测量方法的开发提供信息。


原文出处:
Differential Temporal Dynamics of Axial and Appendicular Ataxia in SCA3. _Movement Disorders_. Published online 2022:12.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1878557, encodeId=4cc418e855721, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Mon Dec 12 09:50:53 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013922, encodeId=46a620139220a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jan 24 01:50:53 CST 2023, time=2023-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077710, encodeId=e28320e771087, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Feb 25 21:50:53 CST 2023, time=2023-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784525, encodeId=ef421e84525bf, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Jan 07 16:50:53 CST 2023, time=2023-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738142, encodeId=1d4a1e3814228, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Wed Dec 07 07:50:53 CST 2022, time=2022-12-07, status=1, ipAttribution=)]
    2022-12-12 anminleiryan
  2. [GetPortalCommentsPageByObjectIdResponse(id=1878557, encodeId=4cc418e855721, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Mon Dec 12 09:50:53 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013922, encodeId=46a620139220a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jan 24 01:50:53 CST 2023, time=2023-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077710, encodeId=e28320e771087, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Feb 25 21:50:53 CST 2023, time=2023-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784525, encodeId=ef421e84525bf, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Jan 07 16:50:53 CST 2023, time=2023-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738142, encodeId=1d4a1e3814228, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Wed Dec 07 07:50:53 CST 2022, time=2022-12-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1878557, encodeId=4cc418e855721, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Mon Dec 12 09:50:53 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013922, encodeId=46a620139220a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jan 24 01:50:53 CST 2023, time=2023-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077710, encodeId=e28320e771087, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Feb 25 21:50:53 CST 2023, time=2023-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784525, encodeId=ef421e84525bf, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Jan 07 16:50:53 CST 2023, time=2023-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738142, encodeId=1d4a1e3814228, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Wed Dec 07 07:50:53 CST 2022, time=2022-12-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1878557, encodeId=4cc418e855721, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Mon Dec 12 09:50:53 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013922, encodeId=46a620139220a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jan 24 01:50:53 CST 2023, time=2023-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077710, encodeId=e28320e771087, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Feb 25 21:50:53 CST 2023, time=2023-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784525, encodeId=ef421e84525bf, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Jan 07 16:50:53 CST 2023, time=2023-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738142, encodeId=1d4a1e3814228, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Wed Dec 07 07:50:53 CST 2022, time=2022-12-07, status=1, ipAttribution=)]
    2023-01-07 cmsvly
  5. [GetPortalCommentsPageByObjectIdResponse(id=1878557, encodeId=4cc418e855721, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Mon Dec 12 09:50:53 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013922, encodeId=46a620139220a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jan 24 01:50:53 CST 2023, time=2023-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077710, encodeId=e28320e771087, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Feb 25 21:50:53 CST 2023, time=2023-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784525, encodeId=ef421e84525bf, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Jan 07 16:50:53 CST 2023, time=2023-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738142, encodeId=1d4a1e3814228, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Wed Dec 07 07:50:53 CST 2022, time=2022-12-07, status=1, ipAttribution=)]

相关资讯

ACS Chem Biol :治疗脆性X染色体综合征疾病的新型分子

近日,来自斯克利普斯研究所佛罗里达分校的研究者开发设计出了一种新型化合物,其可以作为一种新型潜在的疗法来治疗和脆性X染色体综合征(fragile X syndrome)相关的某些疾病。脆性X染色体综合征是一种遗传性疾病,可以引发智力发育迟缓、不育、记忆力减退等病症。 这项研究刊登在了9月4日的国际杂志ACS Chemical Biology上,重点研究了震颤共济失调综合症(tremor atax

Neurology: 浙江大学:脊髓小脑共济失调,神经丝轻链水平与疾病严重程度息息相关

血清NfL水平与SCA2患者的疾病强度相关,并且在接近SCA2临床前患者的估计发病年龄时水平较高。

Mov Disord : 湘雅医院:神经丝轻链蛋白,可有效预测共济失调

bNfL可作为一个潜在的生物标志物来预测遗传性共济失调的发病、严重程度和进展情况

拓展阅读

European Radiology:使用多模态PET/MRI放射组学识别帕金森病和多系统萎缩

放射组学是指从医学影像中高通量提取丰富的影像信息,以辅助医生做出最准确的诊断。现阶段,放射组学已广泛应用于肿瘤学研究,如肿瘤的诊断、分级、疗效评估、预后预测等。

AAN 2024大会盛况回顾,带您领略神经病学新高度!

作为神经科医生,您一定对AAN 2024年大会充满期待。我们为您精心整理了大会内容解读,包括最新研究成果、临床实践经验和未来发展趋势等,让您足不出户就能领略到大会的精彩盛况!点击立即查看别错过!

AAN 2024:突触核蛋白皮肤活检在帕金森病的初步诊断的临床实践

帕金森病早期准确诊断是一项尚未满足的重大需求,这对于早期干预和预后改善有着重要的影响。

Nature Medicine:重塑帕金森病治疗前景:Prasinezumab在早期帕金森病快速进展亚型中的疗效分析

文章探讨了Prasinezumab这种单克隆抗体在早期帕金森病中的潜在的治疗作用。

【帕金森病专题分享】探索帕金森病进展及诊疗全攻略

帕金森病日来临之际,我们特别推出了帕金森病专题系列文章。无论你是初入此领域的新手,还是经验丰富的专家,这里都有你需要的知识和信息。点击立即阅读,共同提升帕金森病诊疗水平!

话题:帕金森病的真相你了解多少?

我们欢迎各位老师,学者们在下方评论区共同探讨帕金森病的各个方面,包括但不限于:帕金森病的介绍、早期症状、体征、预防等都可一起分享出来。